Latest Breaking News On - Christophera viehbacher - Page 1 : comparemela.com

Kirby McInerney LLP Reminds Biogen, Inc (BIIB) Investors

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S..

United statesThomasw elrodChristophera viehbacherBiogen incUs district courtKirby mcinerneyClass periodReata acquisitionNew york basedAttorney advertising

FDA Accepts Eisai s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer s Disease

FDA Accepts Eisai s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer s Disease
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSouth koreaUnited kingdomSaudi arabiaHong kongGreat britainJulie edelmanHaruo naitoChristophera viehbacherTsujim protofibrilsJack coxChuck trianoAlzheimer clinical trial consortiumPublic relations departmentCommunications departmentNational institutes of health

FDA Accepts Eisai s Filing of LEQEMBI® (lecanemab-irmb)

FDA Accepts Eisai s Filing of LEQEMBI® (lecanemab-irmb)
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomSaudi arabiaSouth koreaGreat britainJulie edelmanJack coxChristophera viehbacherChuck trianoTsujim protofibrilsHaruo naitoUnited nations sustainable development goals sdgsEisai europe ltdNational institutes of healthBiogen inc

Bragar Eagel & Squire, P C Reminds Investors That Class

NEW YORK, June 09, 2024 (GLOBE NEWSWIRE) Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that.

United statesNew yorkSouth carolinaKenneth orrRonald kislingBragar eagel squireTodd nightingaleChristophera viehbacherMarion passmoreBrandon walkerUs department of healthDrug administrationExchange commissionEisai co ltdUs bankruptcy courtReata pharmaceuticals inc

Biogen Inc : FDA Accepts Eisai s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer s Disease

TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts

United kingdomHong kongUnited statesSouth koreaSaudi arabiaGreat britainChuck trianoChristophera viehbacherLinkedinand facebookTsujim protofibrilsJack coxHaruo naitoJulie edelmanDrug administrationEuropean unionUnited nations sustainable development goals sdgs